These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 12758236)

  • 1. Radiotherapy with or without mitomycin c in the treatment of locally advanced head and neck cancer: results of the IAEA multicentre randomised trial.
    Grau C; Prakash Agarwal J; Jabeen K; Rab Khan A; Abeyakoon S; Hadjieva T; Wahid I; Turkan S; Tatsuzaki H; Dinshaw KA; Overgaard J
    Radiother Oncol; 2003 Apr; 67(1):17-26. PubMed ID: 12758236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized study of accelerated fractionation radiotherapy with and without mitomycin C in the treatment of locally advanced head and neck cancer.
    Ezzat M; Shouman T; Zaza K; Safwat A; El-Khoudary A; El-Senosi M; Ezzat I
    J Egypt Natl Canc Inst; 2005 Jun; 17(2):85-92. PubMed ID: 16508679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers.
    Dobrowsky W; Naudé J
    Radiother Oncol; 2000 Nov; 57(2):119-24. PubMed ID: 11054514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer.
    Dobrowsky W; Naudé J; Widder J; Dobrowsky E; Millesi W; Pavelka R; Grasl C; Reichel M
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):803-6. PubMed ID: 9845100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial.
    Overgaard J; Mohanti BK; Begum N; Ali R; Agarwal JP; Kuddu M; Bhasker S; Tatsuzaki H; Grau C
    Lancet Oncol; 2010 Jun; 11(6):553-60. PubMed ID: 20382075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperfractionated, accelerated chemoradiation with concurrent mitomycin-C and cisplatin in locally advanced head and neck cancer, a phase I/II study.
    Hehr T; Classen J; Welz S; Ganswindt U; Scheithauer H; Koitschev A; Bamberg M; Budach W
    Radiother Oncol; 2006 Jul; 80(1):33-8. PubMed ID: 16875750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study.
    Poulsen MG; Denham JW; Peters LJ; Lamb DS; Spry NA; Hindley A; Krawitz H; Hamilton C; Keller J; Tripcony L; Walker Q
    Radiother Oncol; 2001 Aug; 60(2):113-22. PubMed ID: 11439206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of concomitant chemoradiation in locally advanced head and neck cancers.
    Lasrado S; Moras K; Pinto GJ; Bhat M; Hegde S; Sathian B; Luis NA
    Asian Pac J Cancer Prev; 2014; 15(10):4147-52. PubMed ID: 24935361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck.
    Haffty BG; Son YH; Wilson LD; Papac R; Fischer D; Rockwell S; Sartorelli AC; Ross D; Sasaki CT; Fischer JJ
    Radiat Oncol Investig; 1997; 5(5):235-45. PubMed ID: 9372546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of continuous mitomycin-C infusion in concomitant radiochemotherapy of primary inoperable advanced head and neck cancer.
    Christiansen H; Hermann RM; Hille A; Schmidberger H; Martin A; Nitsche M; Hess CF; Pradier O
    J Cancer Res Clin Oncol; 2005 Dec; 131(12):815-20. PubMed ID: 16142489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
    Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
    Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas.
    Lee DJ; Cosmatos D; Marcial VA; Fu KK; Rotman M; Cooper JS; Ortiz HG; Beitler JJ; Abrams RA; Curran WJ
    Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):567-76. PubMed ID: 7790241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial.
    Budach V; Stuschke M; Budach W; Baumann M; Geismar D; Grabenbauer G; Lammert I; Jahnke K; Stueben G; Herrmann T; Bamberg M; Wust P; Hinkelbein W; Wernecke KD
    J Clin Oncol; 2005 Feb; 23(6):1125-35. PubMed ID: 15718308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent chemo-radiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: final results of a randomized clinical trial.
    Haffty BG; Wilson LD; Son YH; Cho EI; Papac RJ; Fischer DB; Rockwell S; Sartorelli AC; Ross DA; Sasaki CT; Fischer JJ
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):119-28. PubMed ID: 15629602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
    Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
    Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternating chemoradiotherapy versus partly accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck: results from a phase III randomized trial.
    Corvò R; Benasso M; Sanguineti G; Lionetto R; Bacigalupo A; Margarino G; Pallestrini E; Merlano M; Vitale V; Rosso R
    Cancer; 2001 Dec; 92(11):2856-67. PubMed ID: 11753959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo.
    Paccagnella A; Orlando A; Marchiori C; Zorat PL; Cavaniglia G; Sileni VC; Jirillo A; Tomio L; Fila G; Fede A
    J Natl Cancer Inst; 1994 Feb; 86(4):265-72. PubMed ID: 8158680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
    Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK
    Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer.
    Dische S; Saunders M; Barrett A; Harvey A; Gibson D; Parmar M
    Radiother Oncol; 1997 Aug; 44(2):123-36. PubMed ID: 9288840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09.
    Fu KK; Clery M; Ang KK; Byhardt RW; Maor MH; Beitler JJ
    Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):589-97. PubMed ID: 7790243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.